NASDAQ:ESPREsperion Therapeutics Stock Price, Forecast & News

$43.51

-0.41 (-0.93 %)

(As of 05/22/2020 04:00 PM ET)

Add

Compare

Today's Range

$42.43

Now: $43.51▼

$44.27

50-Day Range

$30.04

MA: $39.54▼

$50.71

52-Week Range

$24.82

Now: $43.51▼

$76.98

Volume481,793 shs

Average Volume693,518 shs

Market Capitalization$1.20 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.17

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Beat the Market (BTM) Rank^™

4.3 Analyst's Opinion

Consensus Rating
Esperion Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $81.42, Esperion Therapeutics has a potential upside of 87.1% from its current price of $43.51.
Amount of Analyst Coverage
Esperion Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Esperion Therapeutics has received 555 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Esperion Therapeutics has received 429 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Esperion Therapeutics has received 56.40% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote “Outperform” if you believe ESPR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Esperion Therapeutics does not currently pay a dividend.
Dividend Growth
Esperion Therapeutics does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Esperion Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $352,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Esperion Therapeutics is held by insiders.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Esperion Therapeutics are expected to decrease in the coming year, from ($5.53) to ($8.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Esperion Therapeutics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Esperion Therapeutics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Esperion Therapeutics has a P/B Ratio of 59.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.03 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ESPR

Previous Symbol

CUSIPN/A

CIK1434868

Webwww.esperion.com

Phone734-887-3903

Debt

Debt-to-Equity Ratio0.06

Current Ratio2.35

Quick Ratio2.33

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$148.36 million

Price / Sales8.10

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.73 per share

Price / Book59.60

Profitability

EPS (Most Recent Fiscal Year)($3.59)

Net Income$-97,170,000.00

Net Margins-5,492.02%

Return on Equity-627.38%

Return on Assets-109.71%

Miscellaneous

Employees76

Outstanding Shares27,620,000

Market Cap$1.20 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

How has Esperion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ESPR stock has increased by 1.4% and is now trading at $43.51. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Esperion Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Esperion Therapeutics.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Esperion Therapeutics.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics Inc (NASDAQ:ESPR) issued its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($2.84) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($3.14) by $0.30. The biopharmaceutical company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $0.39 million. Esperion Therapeutics had a negative return on equity of 627.38% and a negative net margin of 5,492.02%. The business's revenue for the quarter was down 98.8% compared to the same quarter last year. During the same period last year, the firm posted $3.07 earnings per share. View Esperion Therapeutics' earnings history.

What price target have analysts set for ESPR?

12 Wall Street analysts have issued 1 year target prices for Esperion Therapeutics' shares. Their forecasts range from $42.00 to $191.00. On average, they anticipate Esperion Therapeutics' stock price to reach $81.42 in the next twelve months. This suggests a possible upside of 87.1% from the stock's current price. View analysts' price targets for Esperion Therapeutics.

What are Wall Street analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:

1. According to Zacks Investment Research, "Esperion announced encouraging fourth quarter results, wherein earnings and revenues beat estimates. The company received approval for its two drugs, Nexletol and Nexlizet, in February 2020, which was a major boost. The company plans to launch Nexletol in March and Nexlizet in July. Regulatory applications seeking approval for these drugs are under review in Europe. Both candidates have achieved significant reduction in elevated LDL-C levels in hypercholesterolemia patients. The targeted area represents a significant opportunity. Shares have outperformed the industry in the past year. However, Esperion is heavily dependent on the successful commercialization of Nexletol and Nexlizet. The company will likely face stiff competition as its drugs target a crowded market. Esperion also has no other pipeline candidates." (3/26/2020)
2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and lowering our target price to $70 which reflects a more conservative pre-CVOT BPA/combo sales ramp and higher SG&A assumptions. Even with our more conservative forecasts, we believe ESPR is undervalued at these levels (EV of ~$700 million) as we think the stock continues to reflect investor skepticism on the commercial opportunity for BPA/ combo and the company’s cash runway. We view BPA/combo as a clinically de-risked asset with two upcoming and believe BPA’s CVOT design portends a high probability of success. Further, our recent KOL checks have been consistent with our past discussions (see deep dive) in validating what we believe is a meaningful commercial opportunity for BPA/combo in the statin intolerant population." (9/17/2019)
3. Northland Securities analysts commented, "We are now modeling $0.69 in non-GAAP EPS on $97.8 million in revenue for FY/19." (8/29/2019)

Has Esperion Therapeutics been receiving favorable news coverage?

Media headlines about ESPR stock have been trending somewhat positive on Monday, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Esperion Therapeutics earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutEsperion Therapeutics.

Are investors shorting Esperion Therapeutics?

Esperion Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 7,610,000 shares, an increase of 8.6% from the March 31st total of 7,010,000 shares. Based on an average trading volume of 933,400 shares, the days-to-cover ratio is presently 8.2 days. Currently, 28.5% of the shares of the stock are sold short. View Esperion Therapeutics' Current Options Chain.

Who are some of Esperion Therapeutics' key competitors?

Some companies that are related to Esperion Therapeutics include Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Allakos (ALLK), ChemoCentryx (CCXI), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO) and Arrowhead Pharmaceuticals (ARWR). View all competitors.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include Alon USA Partners (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (NVDA), Ship Finance International (SFL), Micron Technology (MU), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Alibaba Group (BABA) and Puma Biotechnology (PBYI).

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:

Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)
Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)
Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)
Mr. Alexander Duke Schwartz, Sr. Director of Investor Relations
Ms. Marianne Andreach, Sr. VP

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Pentwater Capital Management LP (8.38%), BlackRock Inc. (7.09%), State Street Corp (4.01%), Wasatch Advisors Inc. (3.29%), Rhenman & Partners Asset Management AB (2.15%) and Rothschild & Co. Asset Management US Inc. (1.40%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben. View institutional ownership trends for Esperion Therapeutics.

Which institutional investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Nomura Holdings Inc., Tekla Capital Management LLC, BlackRock Inc., Rhenman & Partners Asset Management AB, AXA, Granahan Investment Management Inc. MA, BNP Paribas Arbitrage SA, and Pinnacle Associates Ltd.. View insider buying and selling activity for Esperion Therapeutics.

Which institutional investors are buying Esperion Therapeutics stock?

ESPR stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Invesco Ltd., Rothschild & Co. Asset Management US Inc., Bailard Inc., Pentwater Capital Management LP, Pictet Asset Management Ltd., JPMorgan Chase & Co., and Mutual of America Capital Management LLC. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben. View insider buying and selling activity for Esperion Therapeutics.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $43.51.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $1.20 billion and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is www.esperion.com.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff